Clinical Studies: 2007 Start Date

Psoriasis
Sponsor: Abbott Laboratories
Open-label Study XXXXX in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy.
November 2007 to 2009

Acne
Sponsor: Novum Pharmaceutical Research Services
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing XXXXX to XXXXX in the Treatment of Moderate to Severe Acne Vulgaris.
October 2007 to September 2008

Psoriasis
Sponsor: Abbott Laboratories
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of XXXXX to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
October 2007 to 2009

Sepsis
Sponsor: Eli Lilly and Company
A Study to Quantify the Number of Circulating Endothelial Cells in Patients with Severe Sepsis
October 2007 to November 2009

Type II Diabetes
Sponsor: Merck & Co., Inc
A Phase 3, Randomized Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of XXXXX for the Treatment of Patients With Type 2 Diabetes Mellitus.
September 2007 to October 2008

Psoriasis
Sponsor: Wyeth
A Phase I, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharamcodynamics and Clinical Efficacy of XXXXX Administered Subcutaneously or Intravenously to Subjects with Psoriasis
October 2007 to Present

Type II Diabetes
Sponsor: GlaxoSmithKline
A Phase IIb, 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-
Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of XXXXX, with Byetta as an Open-Label Active Reference, in Subjects with Type 2 Diabetes Mellitus.
April 2007 to February 2008

Chronic Obstructive Pulmonary Disease
Sponsor: Novartis
A Phase II/III, 26-Week Treatment, Multicenter, Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of XXXXX in Patients with Chronic Obstructive Pulmonary Disease Using Blinded as Active Controls.
March 2007 to February 2009

Psoriasis
Sponsor: Centocor, Inc.
A Phase 3, Multicenter, Randomized Study Comparing XXXXX and Etanercept for
the Treatment of Moderate to Severe Plaque Psoriasis. (T12)
March 2007 to October 2009

Clinical Studies